cremophor el has been researched along with Cancer of Ovary in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (63.64) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Allen, C; De Souza, R; Grant, J; Piquette-Miller, M; Vassileva, V | 1 |
| Cook, JA; Fisher, J; Liebmann, JE; Lipschultz, C; Mitchell, JB; Teague, D | 1 |
| Adler, LM; Herzog, TJ; Mutch, DG; Rader, JS; Williams, S | 1 |
| Bishop, J; Linsenmeyer, M; Millward, M; Morton, C; Webster, L; Woodcock, D | 1 |
| Bonfrer, JM; Hageman, PC; Hilkens, JG; Korse, CM; Linders, TC; Molthoff, CF | 1 |
| de Vos, AI; Loos, WJ; Nooter, K; Sparreboom, A; Stoter, G; van der Burg, ME; Verweij, J | 1 |
| Brouwer, E; de Bruijn, P; Gelderblom, H; Nooter, K; Pillay, M; Sparreboom, A; Stoter, G; Verweij, J | 1 |
| Camlett, I; de Jonge, MJ; Gelderblom, H; Hennis, B; Loos, WJ; Mantel, MA; Sparreboom, A; van der Burg, ME; Verweij, J; Wilms, E | 1 |
| Brouwer, E; de Jonge, MJ; Gelderblom, H; Loos, WJ; Nooter, K; Sparreboom, A; Stoter, G; van der Burg, ME; Verweij, J | 1 |
| Buijs, D; Gelderblom, H; Nooter, K; Ouwens, L; Sparreboom, A; Stoter, G; van Zomeren, DM; Verweij, J | 1 |
| Broxterman, HJ; Dekker, H; Lankelma, J; Schuurhuis, GJ; Spoelstra, EC | 1 |
2 trial(s) available for cremophor el and Cancer of Ovary
| Article | Year |
|---|---|
Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Female; Glycerol; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Topotecan | 2001 |
Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel.
Topics: Aged; Antineoplastic Agents, Phytogenic; Ascitic Fluid; Biological Availability; Female; Gastrointestinal Diseases; Glycerol; Hematologic Diseases; Humans; Injections, Intraperitoneal; Injections, Intravenous; Mesothelioma; Middle Aged; Ovarian Neoplasms; Paclitaxel | 2002 |
9 other study(ies) available for cremophor el and Cancer of Ovary
| Article | Year |
|---|---|
Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Biocompatible Materials; Chitosan; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Carriers; Drug Implants; Eggs; Female; Glycerol; Humans; Injections, Intraperitoneal; Mice; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Phosphatidylcholines; Xenograft Model Antitumor Assays | 2007 |
Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines.
Topics: Adenocarcinoma; Astrocytoma; Breast Neoplasms; Cell Survival; Colonic Neoplasms; Dose-Response Relationship, Drug; Female; Glycerol; HeLa Cells; Humans; Lung Neoplasms; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 1993 |
Analysis of exposure times and dose escalation of paclitaxel in ovarian cancer cell lines.
Topics: Cell Cycle; Cell Division; Dimethyl Sulfoxide; Drug Carriers; Drug Screening Assays, Antitumor; Female; Glycerol; Humans; Ovarian Neoplasms; Paclitaxel; Time Factors; Tumor Cells, Cultured | 1994 |
Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype.
Topics: Adult; Aged; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Assay; Carrier Proteins; Drug Resistance; Female; Flow Cytometry; Glycerol; Humans; Membrane Glycoproteins; Middle Aged; Neoplasm Proteins; Ovarian Neoplasms; Paclitaxel; Pharmaceutical Vehicles; Phenotype; Tumor Cells, Cultured | 1993 |
Effect of paclitaxel (Taxol) on CA 125 expression and release by ovarian cancer cell lines.
Topics: Antineoplastic Agents, Phytogenic; CA-125 Antigen; Cell Count; Cystadenocarcinoma, Serous; Female; Glycerol; Humans; Immunohistochemistry; Ovarian Neoplasms; Paclitaxel; Pharmaceutical Vehicles; Tumor Cells, Cultured | 1997 |
Quantitation of Cremophor EL in human plasma samples using a colorimetric dye-binding microassay.
Topics: Antineoplastic Agents, Phytogenic; Calibration; Colorimetry; Coloring Agents; Female; Glycerol; Humans; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Reproducibility of Results; Rosaniline Dyes; Surface-Active Agents | 1998 |
Disposition of [G-(3)H]paclitaxel and cremophor EL in a patient with severely impaired renal function.
Topics: Aged; Antineoplastic Agents, Phytogenic; Chromatography, High Pressure Liquid; Female; Glycerol; Humans; Nephrosclerosis; Ovarian Neoplasms; Paclitaxel; Spectrophotometry, Ultraviolet | 1999 |
Modulation of cisplatin pharmacodynamics by Cremophor EL: experimental and clinical studies.
Topics: Animals; Antineoplastic Agents; Cisplatin; Dose-Response Relationship, Drug; Drug Interactions; Female; Glycerol; Hematologic Diseases; Humans; Infusions, Intravenous; Infusions, Parenteral; Mice; Neoplasm Recurrence, Local; Ovarian Neoplasms; Pharmaceutical Vehicles | 2002 |
P-glycoprotein drug efflux pump involved in the mechanisms of intrinsic drug resistance in various colon cancer cell lines. Evidence for a saturation of active daunorubicin transport.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding Sites; Biological Transport, Active; Cell Survival; Colonic Neoplasms; Daunorubicin; Drug Resistance; Female; Glycerol; Humans; Membrane Glycoproteins; Mice; Neoplasm Proteins; Ovarian Neoplasms; RNA, Messenger; Tumor Cells, Cultured; Verapamil | 1991 |